表紙
市場調查報告書

全球血管收縮素轉化酵素(ACE)抑制劑市場

Angiotensin Converting Enzymes (ACE) Inhibitors Market - Report Analysis till 2026

出版商 Coherent Market Insights 商品編碼 883777
出版日期 內容資訊 英文 163 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球血管收縮素轉化酵素(ACE)抑制劑市場 Angiotensin Converting Enzymes (ACE) Inhibitors Market - Report Analysis till 2026
出版日期: 2019年06月25日內容資訊: 英文 163 Pages
簡介

這份報告提供全球血管收縮素轉化酵素(ACE)抑制劑市場的相關調查,彙整市場趨勢,法規及趨勢,醫藥品·用途·流通管道·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 研究的目的及其假設

  • 研究目的
  • 假設
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 各類醫藥品
    • 各用途
    • 各流通管道
    • 各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,趨勢分析

  • 市場趨勢
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 開發平台分析
  • 流行病學
  • 歷史概要
  • 合併和收購
  • 法規方案
  • PEST分析

第4章 全球血管收縮素轉化酵素(ACE)抑制劑市場:各類醫藥品

  • 簡介
  • benazepuriru
  • perindopuriru
  • torandorapuriru
  • kaputopuriru
  • enaraopuriru
  • rishinopuriru
  • ramipuriru
  • 其他

第5章 全球血管收縮素轉化酵素(ACE)抑制劑市場:各用途

  • 簡介
  • 高血壓
  • 冠狀動脈疾病
  • 心臟衰竭
  • 慢性腎臟病
  • 硬皮症
  • 偏頭痛

第6章 全球血管收縮素轉化酵素(ACE)抑制劑市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球血管收縮素轉化酵素(ACE)抑制劑市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第8章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Pfizer, Inc.
    • AstraZeneca Pharmaceutical Company
    • Novartis AG
    • 第一三共株式會社
    • United Therapeutics Corporation
    • Sanofi S.A.
    • Johnson & Johnson Services, Inc.
    • Merck KGaA
    • 武田藥品工業株式會社
    • Bayer AG
  • 分析師的意見

第9章 章節

  • 參考文獻
  • 調查方法
  • 本公司與銷售方面

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Angiotensin converting enzymes (ACE) inhibitors act by inhibiting the angiotensin converting enzyme (ACE), which is an important component of renin angiotensin system. ACE inhibitors reduce the formation of angiotensin II and facilitate the dilation of blood vessels as well as reduce blood pressure. Angiotensin converting enzyme inhibitors also reduce blood pressure in kidneys. Angiotensin converting enzymes inhibitors (ACE) are effective for the treatment of congestive heart failure, stroke, and high blood pressure. However, overdose of ACE inhibitors may cause kidney failure, allergic reactions, angioedema, and neutropenia.

Market Dynamics:

Increasing research and development activities related to study of ACE inhibitors is expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in February 2016, Monia Lorini, in collaboration with Istituto Di Ricerche Farmacologiche Mario Negri initiated clinical phase II study of ACE inhibitors (Lisinopril) for the treatment of extracapillary glomerulonephritis. This study is for evaluating drug safety and efficacy on the patients. It is expected to complete in December 2019.

Furthermore, in June 2014, Cardiology Research UBC initiated clinical trial phase IV to study the effects of statin including Rosuvastatin and Ramipril - angiotensin converting enzymes inhibitors such as Ramipril on coronary flow reserve and microcirculatory resistance in patients with coronary artery dissection. This study is expected to complete in June 2021.

Overdose of angiotensin converting enzyme (ACE) inhibitors is a major factor restraining growth of the ACE inhibitors market. Overdose of ACE inhibitors may lead to various side effects such as dry cough, hyperkalemia (increased blood potassium level), dizziness, headache, and fatigue. Overdose of ACE inhibitors may also cause cancer. For instance, in October 2018, according to Medical Press (medical center in Melbourne, Australia), angiotensin converting enzymes (ACE) inhibitors are used for the treatment of high blood pressure. However, overdose of ACE inhibitors can increases the risk of lung cancer in patients. These drugs are responsible for the excessive production of bradykinin in the lungs. Excessive bradykinin is the main cause of lung cancer.

Key features of the study:

  • This report provides in-depth analysis of the angiotensin converting enzymes (ACE) inhibitors market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Pfizer, Inc., AstraZeneca, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company and Bayer AG.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for angiotensin converting enzymes (ACE) inhibitors market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application:
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney disease
    • Scleroderma
    • Migraine
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
      • By Application
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney diseases
    • Scleroderma
    • Migraine
      • By Distribution Channels:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
      • By Application
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney disease
    • Scleroderma
    • Migraine
      • By Distribution Channels:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
      • By Application:
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney disease
    • Scleroderma
    • Migraine
      • By Distribution Channels:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
      • By Application
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney disease
    • Scleroderma
    • Migraine
      • By Distribution Channels:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
      • By Application:
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney disease
    • Scleroderma
    • Migraine
      • By Distribution Channels:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
      • By Application:
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney disease
    • Scleroderma
    • Migraine
      • By Distribution Channels:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • AstraZeneca Pharmaceutical Company
    • Novartis AG
    • Daiichi Sankyo Company, Ltd.
    • United Therapeutics Corporation
    • Sanofi S.A.
    • Johnson & Johnson Services, Inc.
    • Merck KGaA
    • Takeda Pharmaceutical Company
    • Bayer AG

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drugs
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Pipeline Analysis
  • Epidemiology
  • Historical Overview
  • Merger and Acquisition
  • Regulatory Scenario
  • PEST Analysis

4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drugs, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Benazepril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Perindopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Trandolapril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Captopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Enalaopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Lisinopril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Ramipril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hypertension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Coronary artery disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Heart failure
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Chronic kidney disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Scleroderma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Migraine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drugs, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drugs, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drugs, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drugs, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drugs, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channels, 2016 - 2026, (US$ Million
    • Market Size and Forecast, By Country/Region, 2016 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drugs, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AstraZeneca Pharmaceutical Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Daiichi Sankyo Company, Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • United Therapeutics Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson Services, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top